Last 32 quarters of trend data · Healthcare · Medical Devices
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -1.14 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 0.46 | 0.56 | 0.47 | 0.73 | 0.82 | 1.09 | 0.75 | 1.71 | 0.82 | 1.80 | 2.10 | 2.38 | 3.25 | 4.06 | 4.29 | 4.74 | 3.20 | 2.45 | 5.14 | 5.54 | 6.46 |
| — | -48.8% | -37.5% | -57.4% | -0.8% | -39.5% | -64.5% | -28.1% | -74.7% | -55.6% | -51.0% | -49.7% | +1.7% | +65.6% | -16.6% | -14.5% | -50.5% | -68.2% | -43.9% | -42.1% | -42.4% | |
| P/B Ratio | 6.10 | — | — | 9.66 | 43.47 | 9.58 | 3.05 | 4.25 | — | 40.39 | 9.69 | 8.59 | 6.41 | 5.88 | 64.99 | 15.40 | 6.13 | — | 16.84 | 9.24 | 7.14 |
| — | — | — | +127.2% | — | -76.3% | -68.5% | -50.5% | — | +586.4% | -85.1% | -44.3% | +4.6% | — | +285.8% | +66.7% | -14.1% | — | +226.4% | +108.7% | +68.5% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 67.7% | 72.3% | 65.7% | 65.9% | 67.5% | 69.8% | 67.6% | 63.6% | 67.8% | 68.8% | 68.3% | 68.4% | 69.0% | 70.4% | 66.3% | 70.3% | 65.6% | 62.9% | 60.7% | 67.6% | 60.1% |
| — | +3.5% | -2.8% | +3.7% | -0.5% | +1.5% | -1.1% | -7.0% | -1.7% | -2.2% | +3.0% | -2.8% | +5.2% | +11.8% | +9.2% | +4.1% | +9.1% | -6.5% | +3.0% | +4.6% | -2.8% | |
| Operating Margin | -42.0% | -48.1% | -55.2% | -31.9% | -36.5% | -45.0% | -56.5% | -47.3% | -49.4% | -71.9% | -29.1% | -72.2% | -67.6% | -71.5% | -94.5% | -81.2% | -85.0% | -98.4% | -119.6% | -91.4% | -94.3% |
| — | -7.0% | +2.3% | +32.7% | +26.1% | +37.5% | -94.5% | +34.5% | +27.0% | -0.6% | +69.2% | +11.1% | +20.4% | +27.3% | +21.0% | +11.1% | +9.8% | -1.7% | +3.3% | +23.2% | +27.0% | |
| Net Margin | -48.4% | -58.4% | -64.4% | -43.3% | -41.6% | -49.1% | -60.8% | -52.2% | -54.7% | -78.3% | -34.1% | -75.8% | -72.8% | -74.4% | -101.0% | -85.9% | -96.0% | -122.4% | -132.0% | -102.9% | -108.0% |
| — | -18.8% | -5.9% | +17.0% | +24.0% | +37.3% | -78.4% | +31.2% | +24.8% | -5.2% | +66.2% | +11.7% | +24.2% | +39.2% | +23.5% | +16.6% | +11.1% | -12.1% | +4.7% | +25.1% | +25.5% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -223.4% | — | -2207.4% | -229.8% | -160.2% | -72.7% | -48.4% | -83.0% | — | -146.1% | -34.0% | -52.2% | -31.1% | -50.0% | -137.9% | -53.1% | -98.5% | -299.9% | -72.1% | -36.0% | -26.4% |
| — | — | -4464.2% | -176.8% | — | +50.2% | -42.1% | -59.2% | — | -192.0% | +75.3% | +1.7% | +68.5% | +83.3% | -91.3% | -47.2% | -273.5% | -1292.6% | -301.9% | -143.7% | -104.9% | |
| ROA | -46.0% | -17.4% | -16.2% | -12.6% | -13.3% | -13.7% | -13.7% | -13.1% | -18.3% | -19.1% | -7.6% | -15.6% | -12.1% | -14.1% | -19.0% | -13.5% | -16.4% | -23.9% | -18.4% | -13.1% | -11.6% |
| — | -26.8% | -18.5% | +3.6% | +27.3% | +28.2% | -81.2% | +15.8% | -51.9% | -35.5% | +60.2% | -15.2% | +26.3% | +41.0% | -3.1% | -3.2% | -41.2% | -120.1% | -86.6% | -50.6% | -42.9% | |
| ROIC | -169.0% | -63.4% | -69.3% | -39.9% | -37.8% | -41.0% | -43.7% | -34.0% | -39.3% | -47.9% | -21.7% | -63.4% | -50.0% | -50.1% | -59.6% | -61.8% | -71.6% | -77.9% | -88.4% | -87.9% | -96.4% |
| — | -54.5% | -58.7% | -17.2% | +3.9% | +14.4% | -101.6% | +46.3% | +21.3% | +4.4% | +63.6% | -2.7% | +30.2% | +35.6% | +32.7% | +29.7% | +25.7% | +10.1% | +0.2% | +4.5% | -31.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 8.82 | — | — | 8.82 | 26.98 | 4.56 | 2.31 | 1.51 | — | 14.42 | 2.87 | 2.26 | 1.37 | 1.04 | 13.24 | 2.90 | 1.72 | — | 3.19 | 1.57 | 1.13 |
| — | — | — | +482.6% | — | -68.4% | -19.5% | -33.2% | — | +1284.2% | -78.3% | -21.8% | -20.6% | — | +315.1% | +85.0% | +52.4% | — | +329.2% | +149.2% | +107.4% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.20 | 2.99 | 3.61 | 4.20 | 3.30 | 3.19 | 4.22 | 5.01 | 2.62 | 3.41 | 4.13 | 4.23 | 5.36 | 6.84 | 3.71 | 5.03 | 4.86 | 3.83 | 4.10 | 5.58 | 6.99 |
| — | -6.1% | -14.5% | -16.0% | +26.1% | -6.5% | +2.2% | +18.4% | -51.2% | -50.1% | +11.1% | -16.0% | +10.3% | +78.6% | -9.3% | -9.8% | -30.5% | -60.5% | -69.3% | -55.7% | -58.0% | |
| Quick Ratio | 3.59 | 2.38 | 2.92 | 3.59 | 2.62 | 2.59 | 3.40 | 4.19 | 1.81 | 2.52 | 3.23 | 3.45 | 4.43 | 5.75 | 2.67 | 4.08 | 4.06 | 2.96 | 3.26 | 4.86 | 6.32 |
| — | -8.0% | -14.1% | -14.2% | +44.7% | +2.9% | +5.3% | +21.3% | -59.1% | -56.3% | +21.2% | -15.5% | +9.0% | +94.2% | -18.3% | -16.0% | -35.7% | -67.4% | -73.9% | -59.5% | -60.2% | |
| Interest Coverage | -6.36 | -4.40 | -4.95 | -4.43 | -6.16 | -7.32 | -8.20 | -6.29 | -6.72 | -8.47 | -3.25 | -8.58 | -7.21 | -7.31 | -8.65 | -7.50 | -9.38 | -12.64 | -10.92 | -8.35 | -7.97 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 32 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TELA stock.
TELA Bio, Inc.'s current P/E is -1.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
TELA Bio, Inc.'s current operating margin is -42.0%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking TELA Bio, Inc.'s business trajectory between earnings reports.